Table of Contents
Hepatitis Research and Treatment
Volume 2010 (2010), Article ID 703602, 7 pages
http://dx.doi.org/10.1155/2010/703602
Review Article

Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors

Department of Gastroenterology and Hepatology, Musashino Red-Cross Hospital, Kyonancho 1-26-1, Musashinoshi, 180-8610 Tokyo, Japan

Received 25 April 2010; Revised 29 June 2010; Accepted 19 July 2010

Academic Editor: Ming-Lung Yu

Copyright © 2010 Namiki Izumi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Asahina, K. Tsuchiya, I. Hirayama et al., “Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection,” Hepatology, vol. 52, no. 2, pp. 518–527, 2010. View at Google Scholar
  2. N. Enomoto, I. Sakuma, Y. Asahina et al., “Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection,” New England Journal of Medicine, vol. 334, no. 2, pp. 77–81, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Iino, F. Ichida, A. Sakuma et al., “A randomized clinical trial with natural interferon-α monotherapy for 24 or 48 weeks on patients with chronic hepatitis C having genotype 1b infection in high viral titers,” Hepatology Research, vol. 24, no. 4, pp. 338–345, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Squadrito, M. E. Orlando, I. Cacciola et al., “Long-term response to interferon alpha is unrelated to “interferon sensitivity determining region” variability in patients with chronic hepatitis C virus-1b infection,” Journal of Hepatology, vol. 30, no. 6, pp. 1023–1027, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Shen, T. Hu, L. Shen, L. Gao, W. Xie, and J. Zhang, “Mutations in ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic hepatitis C virus genotype 1b infection,” Journal of Gastroenterology and Hepatology, vol. 22, no. 11, pp. 1898–1903, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Pascu, P. Martus, M. Höhne et al., “Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences,” Gut, vol. 53, no. 9, pp. 1345–1351, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. S. J. Hadziyannis, H. Sette Jr., T. R. Morgan et al., “Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose,” Annals of Internal Medicine, vol. 140, no. 5, pp. 346–355, 2004. View at Google Scholar · View at Scopus
  8. M. P. Manns, J. G. McHutchison, S. C. Gordon et al., “Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial,” Lancet, vol. 358, no. 9286, pp. 958–965, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Iino, E. Tomita, H. Kumada et al., “Prediction of treatment outcome with daily high-dose IFN α-2b plus ribavirin in patients with chronic hepatitis C with genotype 1b and high HCV RNA levels: relationship of baseline viral levels and viral dynamics during and after therapy,” Hepatology Research, vol. 30, no. 2, pp. 63–70, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Yamada, S. Iino, T. Okuno et al., “Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-α-2a plus ribavirin dose reductions and host-related factors,” Clinical Drug Investigation, vol. 28, no. 1, pp. 9–16, 2008. View at Google Scholar · View at Scopus
  11. N. Akuta, F. Suzuki, Y. Kawamura et al., “Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels,” Journal of Hepatology, vol. 46, no. 3, pp. 403–410, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Shirakawa, A. Matsumoto, S. Joshita et al., “Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors,” Hepatology, vol. 48, no. 6, pp. 1753–1760, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Asahina, N. Izumi, I. Hirayama et al., “Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response,” Gastroenterology, vol. 134, no. 5, pp. 1396–1405, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Ge, J. Fellay, A. J. Thompson et al., “Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance,” Nature, vol. 461, no. 7262, pp. 399–401, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Tanaka, N. Nishida, M. Sugiyama et al., “Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C,” Nature Genetics, vol. 41, no. 10, pp. 1105–1109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Ferenci, H. Laferl, T. Scherzer et al., “Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response,” Gastroenterology, vol. 135, no. 2, pp. 451–458, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Izumi, S. Nishiguchi, K. Hino et al., “Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009),” Hepatology Research, vol. 40, no. 4, pp. 347–368, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. M. G. Ghany, D. B. Strader, D. L. Thomas, and L. B. Seeff, “Diagnosis, management, and treatment of hepatitis C: an update,” Hepatology, vol. 49, no. 4, pp. 1335–1374, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Berg, M. von Wagner, S. Nasser et al., “Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin,” Gastroenterology, vol. 130, no. 4, pp. 1086–1097, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. J. M. Sánchez-Tapias, M. Diago, P. Escartín et al., “Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment,” Gastroenterology, vol. 131, no. 2, pp. 451–460, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Ferenci, H. Laferl, T. M. Scherzer et al., “Customizing treatment with peginterferon alfa-2a (40kD)(PEGASYS®) plus ribavirin (COPEGUS®) in patient with HCV genotype 1 or 4 infection: interim results of a prospective randomized trial,” Hepatology, vol. 44, no. 336a, 2006. View at Google Scholar
  22. B. L. Pearlman, C. Ehleben, and S. Saifee, “Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders,” Hepatology, vol. 46, no. 6, pp. 1688–1694, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Buti, Y. Lurie, N. G. Zakharova et al., “Extended treatment duration in chronic hepatitis C genotype 1-infected slow responders: final results of the SUCCESS study,” Journal of Hepatology, vol. 50, supplement 1, p. S58, abstract 141, 2009. View at Google Scholar
  24. F. Kurbanov, Y. Tanaka, K. Matsuura et al., “Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin,” Journal of Infectious Diseases, vol. 201, no. 11, pp. 1663–1671, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Enomoto and S. Maekawa, “HCV genetic elements determining the early response to peginterferon and ribavirin therapy,” Intervirology, vol. 53, no. 1, pp. 66–69, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Okanoue, Y. Itoh, H. Hashimoto et al., “Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study,” Journal of Gastroenterology, vol. 44, no. 9, pp. 952–963, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Nakagawa, N. Sakamoto, M. Ueyama et al., “Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection,” Journal of Gastroenterology, vol. 45, no. 6, pp. 656–665, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Bouzgarrou, E. Hassen, W. Mahfoudh et al., “NS5AISDR-V3 region genetic variability of Tunisian HCV-1b strains: correlation with the response to the combined interferon/ribavirin therapy,” Journal of Medical Virology, vol. 81, no. 12, pp. 2021–2028, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. M. L. Shiffman, M. G. Ghany, T. R. Morgan et al., “Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C,” Gastroenterology, vol. 132, no. 1, pp. 103–112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Fellay, A. J. Thompson, D. Ge et al., “ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C,” Nature, vol. 464, no. 7287, pp. 405–408, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Zeuzem, “Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?” Annals of Internal Medicine, vol. 140, no. 5, pp. 370–381, 2004. View at Google Scholar · View at Scopus
  32. H. S. Conjeevaram, D. E. Kleiner, J. E. Everhart et al., “Race, insulin resistance and hepatic steatosis in chronic hepatitis C,” Hepatology, vol. 45, no. 1, pp. 80–87, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Tarantino, P. Conca, P. Sorrentino, and M. Ariello, “Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis,” Journal of Gastroenterology and Hepatology, vol. 21, no. 8, pp. 1266–1268, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. M. R. Charlton, P. J. Pockros, and S. A. Harrison, “Impact of obesity on treatment of chronic hepatitis C,” Hepatology, vol. 43, no. 6, pp. 1177–1186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. M. J. Walsh, J. R. Jonsson, M. M. Richardson et al., “Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1,” Gut, vol. 55, no. 4, pp. 529–535, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Kurosaki, K. Matsunaga, I. Hirayama et al., “A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis,” Hepatology Research, vol. 40, no. 3, pp. 251–260, 2010. View at Google Scholar